Ironwood FY2024 revenue $351M, net income positive; apraglutide NDA rolling initiated

IRONWOOD PHARMACEUTICALS INC

2024-FY EPS reported $0.01 revenue$351,410,000

Total revenue $90.5M in Q4 and $351.4M for FY2024, down 23% YoY from $442.7M in FY2023.
GAAP net income $1.8M in FY2024 vs. loss of $1.0B in FY2023 (prior year included impairment).
Adjusted EBITDA $100.6M for FY2024, a significant improvement from $(884.8)M in FY2023.
LINZESS prescription demand grew 11% YoY in FY2024; company achieved 2024 financial guidance.
Rolling NDA submission for apraglutide (SBS) initiated, on track for completion in Q3 2025; OLE data showed 27 patients achieving enteral autonomy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.